Netakimab Clinical Trial reveals its efficacy for treating Psoriasis

Jun 7, 2020 by Ameer Helles

The recent PATERA clinical trial evaluated 194 patients with psoriatic arthritis for response to the drug netakimab in a 24-week trial that monitored disease activity and skin outbreaks.

Netakimab, the first IL-17A monoclonal antibody, is a groundbreaking drug approved for the treatment of moderate-to-severe plaque psoriasis in patients who have indications for systemic therapy or phototherapy.



The trial resulted in 82% of the participants who took netakimab achieving ACR20 (American College of Rheumatology criteria) in 24 weeks, compared to only 9% on the placebo, and 70% achieved ACR50 compared to 6% on placebo.

The results of the clinical trials showed that 82% of the netakimab arm and 9 percent of the placebo arm achieved ACR20 at week 24. Seventy percent of patients in the netakimab arm reached ACR50 compared with 6 percent of patients in the placebo arm.

The 24-week treatment with netakimab also resulted in significant improvement in skin manifestations in patients with psoriatic arthritis. About half the patients with 3% of body surface involvement reached complete skin clearance, and those with inflammatory back pain experienced relief from symptoms. 

The drug showed low immunogenicity and a mild to moderate range of adverse effects. No significant adverse effects have been reported, and no anti-drug antibodies have been detected.

---